This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hindiyeh, M. Y.
Right arrow Articles by Mendelson, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hindiyeh, M. Y.
Right arrow Articles by Mendelson, E.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, March 2009, p. 560-565, Vol. 47, No. 3
0095-1137/09/$08.00+0     doi:10.1128/JCM.01756-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Characterization of Large Mumps Outbreak among Vaccinated Palestinian Refugees {triangledown}

Musa Y. Hindiyeh,1* Yair Aboudy,1 Mahmoud Wohoush,2 Lester M. Shulman,1,4 Daniela Ram,1 Tal Levin,1 Tamar Frank,1 Flavia Riccardo,3 Mohamad Khalili,2 Elias-Shlash Sawalha,2 Maysoun Obeidi,2 Guido Sabatinelli,3 Zehava Grossman,1,4 and Ella Mendelson1,5

Central Virology Laboratory, Public Health Services, Ministry of Health, Chaim Sheba Medical Center, Tel-Hashomer, Israel,1 UNRWA, Health Department West Bank Field Office UNRWA, West Bank,2 UNRWA, Health Department HQ Amman, Jordan,3 Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel,4 Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, Israel5

Received 11 September 2008/ Returned for modification 18 November 2008/ Accepted 7 January 2009

During a large mumps virus (MuV) outbreak which occurred in the Palestinian refugee camps of the West Bank, 68.1% (2,636/3,871) of the cases were vaccinated with one dose of trivalent measles, mumps, and rubella (MMR) vaccine. Attack rates by camp ranged from less than 1 case per 1,000 people in the population to 43/1,000 (overall, 11/1,000). The outbreak lasted from December 2003 to June 2005, with two peaks, one from April to May 2004 and the other from March to April 2005. To control the outbreak, a mass MMR vaccination campaign was conducted in May 2005. Evaluation of the immune status of cases (n = 59) and healthy controls (n = 51) revealed high levels of mumps immunoglobulin G (IgG) and a low MuV-specific IgM in clinical cases indicative of a booster immune response. This suggested a secondary rather than a primary infection due to the insufficient protection conferred by the single vaccine dose included in the vaccination program. This prediction was further confirmed by the low seroprevalence (68.6%) found in the healthy control group, which was below the threshold level required for MuV herd immunity. Mumps diagnosis was established mainly by reverse transcription-PCR in clinical samples obtained within 48 h from the onset of disease. Of the parotid fluids and nasopharyngeal aspirates analyzed, 92% were positive for MuV RNA, while only 33% of the urine samples were positive. Phylogenetic analysis of the MuV SH gene identified the outbreak strain as the H genotype, which has been in circulation worldwide at least since 1989.


* Corresponding author. Mailing address: Viral Real-Time PCR Diagnosis, Central Virology Laboratory, Chaim Sheba Medical Center, Tel-Hashomer 52621, Israel. Phone: 972-3-530-2066. Fax: 972-3-530-2457. E-mail: hindiyeh{at}yahoo.com

{triangledown} Published ahead of print on 14 January 2009.


Journal of Clinical Microbiology, March 2009, p. 560-565, Vol. 47, No. 3
0095-1137/09/$08.00+0     doi:10.1128/JCM.01756-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.